With a market cap of $64.6 billion, Cencora, Inc. (COR) is a leading global pharmaceutical solutions company that partners with pharmaceutical innovators to improve access to therapies and support better health outcomes for people and animals worldwide. The company provides secure, reliable distribution of pharmaceuticals, healthcare products, and related solutions to care providers, helping create healthier futures across the global healthcare industry.
The Conshohocken, Pennsylvania-based company is slated to announce its fiscal Q4 2026 results before the market opens on Wednesday, Nov. 4. Ahead of the event, analysts forecast Cencora to report an adjusted EPS of $4.51, up 17.5% from $3.84 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarterly reports while missing on another occasion.